Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons

David L. Thomas, John G. Bartlett, Marion G. Peters, Kenneth E. Sherman, Mark S. Sulkowski, Paul A. Pham

Research output: Contribution to journalArticle

Abstract

In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

Original languageEnglish (US)
Pages (from-to)979-983
Number of pages5
JournalClinical Infectious Diseases
Volume54
Issue number7
DOIs
StatePublished - Apr 1 2012

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons'. Together they form a unique fingerprint.

  • Cite this